MetaVia Advances Obesity Drug Candidate with Dose-Escalation Trial Approval
Event summary
- MetaVia received IRB approval to initiate Part 3 of Phase 1 clinical trials for DA-1726, a GLP-1 and glucagon dual agonist.
- The trial will enroll 40 obese adults and evaluate one-step (48mg) and two-step (64mg) dose titration regimens over 16 weeks.
- Previous data showed the 48mg dose produced approximately 9% weight loss and improved blood sugar control.
- Initial dosing is expected in April 2026, with data anticipated in Q4 2026.
- DA-1726 has demonstrated improved weight loss and lipid-lowering effects compared to competitors in preclinical models.
The big picture
The obesity treatment market is experiencing explosive growth, driven by the success of GLP-1 receptor agonists. MetaVia’s DA-1726, a dual GLP-1/glucagon agonist, aims to differentiate itself through improved efficacy and tolerability. The Phase 1 data will be critical in determining whether DA-1726 can carve out a significant share of this rapidly expanding market, which is currently dominated by Novo Nordisk and Eli Lilly.
What we're watching
- Tolerability Risk
- The titration strategy aims to optimize tolerability, but higher doses (64mg) introduce greater risk of adverse events that could derail development.
- Competitive Landscape
- The trial’s results will be closely scrutinized against existing GLP-1 therapies like semaglutide and tirzepatide, particularly regarding efficacy and side-effect profiles.
- MASH Potential
- How the observed liver benefit signals in earlier trials translate to efficacy in the Phase 1 titration study will be a key indicator of DA-1726's potential in the MASH market.
Related topics